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Objective: The beneﬁt of fenestrated endovascular aortic aneurysm repair (FEVAR) compared with open surgical repair
(OSR) of complex abdominal aortic aneurysms (CAAAs) is unknown. This study compares 30-day outcomes of these
procedures from two high-volume centers where FEVAR was undertaken for high-risk patients.
Methods: Patients undergoing FEVAR with commercially available devices and OSR of CAAAs (total suprarenal/supra-
visceral clamp position) were propensity matched by demographic, clinical, and anatomic criteria to identify similar pa-
tient cohorts. Perioperative outcomes were evaluated using univariate and multivariate methods.
Results: From July 2001 to August 2012, 59 FEVAR and 324 OSR patients were identiﬁed. After 1:4 propensity
matching for age, gender, hypertension, congestive heart failure, coronary disease, chronic obstructive pulmonary disease,
stroke, diabetes, preoperative creatinine, and anticipated/actual aortic clamp site, the study cohort consisted of 42
FEVARs and 147 OSRs. The most frequent FEVAR construct was two renal fenestrations, with or without a single
mesenteric scallop, in 50% of cases. An average of 2.9 vessels were treated per patient. Univariate analysis demonstrated
FEVAR had higher rates of 30-day mortality (9.5% vs 2%; P[ .05), any complication (41% vs 23%; P[ .01), procedural
complications (24% vs 7%; P < .01), and graft complications (30% vs 2%; P < .01). Multivariable analysis showed FEVAR
was associated with an increased risk of 30-day mortality (odds ratio [OR], 5.1; 95% conﬁdence interval [CI], 1.1-24;
P [ .04), any complication (OR, 2.3; 95% CI, 1.1-4.9; P [ .01), and graft complications (OR, 24; 95% CI, 4.8-66;
P < .01).
Conclusions: FEVAR, in this two-center study, was associated with a signiﬁcantly higher risk of perioperative mortality
and morbidity compared with OSR for management of CAAAs. These data suggest that extension of the paradigm shift
comparing EVAR with OSR for routine AAAs to patients with CAAAs is not appropriate. Further study to establish
proper patient selection for FEVAR instead of OSR is warranted before widespread use should be considered. (J Vasc
Surg 2014;60:858-64.)During the last 10 years, endovascular aneurysm repair
(EVAR) has been replacing open surgical repair (OSR) to
become the predominant modality of treatment for stan-
dard infrarenal aortic aneurysms.1,2 The beneﬁts of
EVAR of abdominal aortic aneurysm (AAA) rather than
OSR are clearly established by large multicenter random-
ized trials.3-5 Nevertheless, for complex aneurysms
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://dx.doi.org/10.1016/j.jvs.2014.04.011OSR has remained the standard of care. Early outcomes
of OSR of complex abdominal aortic aneurysms (CAAAs)
in large centers have been excellent, with comparable 30-
day mortality to infrarenal disease.6 Early outcomes of
EVAR with fenestrated grafts (FEVAR) for CAAAs are
also very encouraging, with very low mortality rates and
excellent technical success.7
Notwithstanding, studies comparing open and endo-
vascular repair are sparse, and this lack of data prevents
our ability to determine if the relatively straightforward
paradigm shift that occurred from OSR to EVAR, will
also be possible when applying it to EVAR of complex
aortic disease. Therefore, the aim of this study was to
compare 30-day outcomes of FEVAR procedures and
OSR for the treatment of CAAAs.
METHODS
Study population. This retrospective cohort study
compared 30-day outcomes of OSR and FEVAR repair
of CAAAs by using prospectively collected data from two
high-volume centers: Henri Mondor Hospital (Créteil,
France) and the Massachusetts General Hospital (MGH)
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cedures have been performed at both centers,8-11 including
complex aneurysms12 and thoracoabdominal aneurysms.13
Data collected represent the clinical experience from July
2001 to August 2012. All OSRs were performed at the
MGH and all FEVARs at Henri Mondor. Each in-
stitution’s Institutional Review Board approved the study
and waived patient consent for this retrospective medical
record review.
All FEVAR patients were considered high-risk patients
according to criteria deﬁned by the Agence Française de
Sécurité Sanitaire des Produits de Santé (AFSSAPS).
FEVAR patients were deemed unsuitable for OSR by the
operating surgeon. Because of anatomic involvement with
the aneurysm of renal or visceral arteries, or both, these pa-
tients were not candidates for conventional EVAR. Only
patients who would have required an actual or anticipated
completely suprarenal or more proximal clamp position
were included in the study. For the FEVAR group, the
operating surgeon deﬁned the anticipated clamp site after
reviewing a preoperative computed tomography (CT)
scan. For OSR, the actual clamp site was determined dur-
ing surgery.
Data included demographic, anatomic information
with aneurysm morphology, surgical procedural details,
postoperative events, and radiographic follow-up. Renal
function was monitored preoperatively and postoperatively.
Renal insufﬁciency was deﬁned by a creatinine level
$1.5 mg/dL.
The study excluded patients referred for extent I-IV
thoracoabdominal aneurysms, ruptured or symptomatic
aneurysms, patients with a redo aortic surgery or a history
of aortic intervention, and patients with actual or antici-
pated infrarenal clamp position.
End points. The primary end point was 30-day mor-
tality. Secondary outcomes included any complication
(including procedural and graft complications, cardiac,
renal, and respiratory complications), procedural, and graft
complications #30 days postoperatively. Cardiac compli-
cations were deﬁned as acute myocardial infarction or
emergent arrhythmia. Pulmonary complications consisted
of ventilation >48 hours postoperatively, reintubation,
pneumonia, and pulmonary embolism. Renal failure was
deﬁned when the patient required transient or deﬁnitive
hemodialysis postoperatively. New-onset renal insufﬁciency
was deﬁned by an increase of creatinine of 0.5 mg/dL over
baseline, and with a creatinine increase to >1.5 mg/dL.
Procedural complications encompassed postoperative
bleeding and a return to the operating room. Graft com-
plications included any graft-related event during surgery
or in the postoperative period.
Statistical analysis. To obtain comparable cohorts, a
propensity score (PS) was generated using multivariable
regression modeling to assess each patient’s propensity
for undergoing FEVAR repair. Statistically signiﬁcant
(P < .05) determinants of the PS for FEVAR repair
included gender, age, chronic obstructive pulmonary dis-
ease (COPD), coronary artery disease (CAD), congestiveheart failure (CHF), history of coronary intervention, dia-
betes, and actual or anticipated clamp location. PS match-
ing was then performed using the caliper method,
matching each case (FEVAR) with four controls (OSR)
#0.2 standard deviations of the PS. This resulted in well-
matched cases and controls for analysis.
Clinical features, demographic, and outcomes data are
presented as the number in each category and the percent-
age this number represents. Data for continuous variables
are presented as the mean 6 standard deviation. Univari-
ate analysis was performed using the c2 or the Fisher exact
test for discrete variables, the t-test with equal variances
for normal continuous variables, and the Wilcoxon rank
sum test for non-normally distributed continuous or
ordinal variables. Multivariate regression analysis was per-
formed to identify independent predictors of primary and
secondary outcomes. Odds ratios (ORs) and 95% conﬁ-
dence intervals (CIs) are presented. A two-sided P value
of <.05 was considered statistically signiﬁcant. Statistical
analysis was performed using SAS 9.2 software (SAS Insti-
tute, Cary, NC).
RESULTS
Demographics. During the study period, 324 pa-
tients underwent OSR at the MGH and 59 underwent
FEVAR at Henri Mondor Hospital. Five patients from
the OSR group and four from the FEVAR cohort were
excluded due to an actual/anticipated partial suprarenal
clamping site, based on operative records or CT scan re-
view. Demographic and anatomic data are presented in
Table I. Before propensity matching, patients in the
FEVAR group had a higher incidence of CHF, CAD,
COPD, and diabetes than those in the OSR group. The
FEVAR patients also had a higher proportion of antici-
pated supravisceral clamp position, which included
clamping above the superior mesenteric artery (SMA) or
celiac artery. After propensity matching, there were 42
patients in the FEVAR group and 147 in the OSR group.
Propensity matching resulted in correction of all differ-
ences in baseline clinical characteristics, including clamp
location (Table I).
All of the fenestrated grafts used were commercially
approved devices, with 95% being Cook Z-FEN (Cook
Australia, Brisbane, Queensland, Australia). The distribu-
tion of visceral vessel involvement in FEVAR included
the following: 30% of the EVAR patients had two vessels
treated, 50% had three fenestrations/scallops, and 20%
had four vessels treated for the implanted device, resulting
in an average number of 2.9 vessels treated per patient.
Grafts conﬁgurations are presented in Table II. The proce-
dure for implantation of fenestrated grafts has been previ-
ously described.14,15
For the OSR patients, 91% were treated through a left
ﬂank thoracoabdominal incision. Surgical reconstruction
methods for CAAAs have also been previously detailed.12
Univariate analysis of 30-day outcomes. In the
propensity-matched cohorts, 30-day mortality was 2% for
OSR vs 9.5% for FEVAR (P ¼ .04). Two patients in the
Table II. Stent graft conﬁgurations in fenestrated
endovascular aneurysm repair (FEVAR) group
Graft conﬁguration Patients, No.
1 fenestration, 1 scallop 1
1 fenestration, 2 scallops 3
2 fenestrations 12
2 fenestrations, 1 scallop 9
3 fenestrations 9
3 fenestrations, 1 scallop 7
4 fenestrations 1
Table I. Clinical and demographic features
Variable
Unmatched cohort Propensity-matched cohort
FEVAR (n ¼ 55) OSR (n ¼ 319) P FEVAR (n ¼ 42) OSR (n ¼ 147) P
Age, mean 6 SD, years 73 6 9.3 74 6 8.0 .8 73 6 10 73 6 7.8 .8
Male sex, % 91 70 .001 88 82 .4
History of aneurysm, % 7.3 5.3 .2 4.8 5.4 .3
Hypertension, % 65 90 <.0001 74 80 .4
MI, % 35 34 .9 26 36 .2
CHF, % 24 7.5 .0002 14 12 .6
CAD, % 56 23 <.0001 43 34 .3
COPD, % 44 24 .003 36 25 .2
CVA, % 11 7.9 .1 7.1 7.5 .3
Diabetes, % 22 11 .02 19 14 .5
Smoking, % 60 78 .005 67 71 .6
CRI, % 24 19 .5 26 20 .4
Clamp, %
Suprarenal 53 76 .0003 57 63 .5
Supravisceral 47 24 .0003 43 37 .5
CAD, Coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CRI, chronic renal insufﬁciency; CVA, cere-
brovascular accident; FEVAR, fenestrated endovascular aneurysm repair; MI, myocardial infarction; OSR, open surgical repair; SD, standard deviation.
Table III. Univariate analysis of perioperative outcomes
Outcome
FEVAR
(n ¼ 42) (%)
OSR
(n ¼ 147) (%) P
30-day mortality 9.5 2 .04
Complication
Any 43 23 .01
Cardiac 4.8 9.5 .2
Pulmonary 12 10 .2
Renal 7.1 2.7 .1
Procedural 24 8 .004
Graft 33 2 <.0001
FEVAR, Fenestrated endovascular aneurysm repair; OSR, open surgical
repair.
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multiple organ failure and mesenteric ischemia, and one
died of respiratory failure due to pneumonia.
The proportion of any complication was higher in the
FEVAR group, with complications in 43% of FEVAR
compared with 23% for OSR (P ¼ .01). Procedural compli-
cations were more frequent in the FEVAR group (24%)
than in OSR group (7.5%) (P ¼ .004). Graft complications,
excluding all endoleaks, were also signiﬁcantly higher in the
FEVAR group than in the OSR group (33% vs 2%; P <
.0001). The occurrence of organ system speciﬁc, cardiac,
pulmonary, or renal complications was not signiﬁcantly
different between the groups. These results are summa-
rized in Table III. Procedural complications are detailed
in Table IV.
Multivariate analysis. In the propensity-matched data
set, multivariable analysis identiﬁed FEVAR as an inde-
pendent predictor of 30-day mortality (OR, 5.1; 95% CI,
1.1-24; P ¼ .04). FEVAR was also independently associ-
ated with the occurrence of any complication (OR, 2.3;
95% CI, 1.1-4.9; P ¼ .03), any procedural complication
(OR, 4.3; 95% CI, 1.5-12; P ¼ .006), and was a statistically
signiﬁcant predictor of a graft complication (OR, 24; 95%CI, 6.5-89; P < .0001). COPD was independently asso-
ciated with the occurrence of any complication (OR, 3.3;
95% CI, 1.7-6.7; P ¼ .0008) and procedural complications
(OR, 4.3; 95% CI, 1.6-11.5; P ¼ .0043). A history of
myocardial infarction was found to independently predict
the occurrence of procedural complications (OR, 3.9; 95%
CI, 1.4-11; P ¼ .0085). These data are presented in
Table V.
DISCUSSION
Owing to the paradigm shift from open surgery to
endovascular repair for the treatment of standard infrarenal
AAA during the last decade, it was consistent to consider
that the same shift might have occurred for the treatment
of complex aneurysms with endovascular repair. FEVAR,
however, is a more complex and demanding procedure
than EVAR for infrarenal aortic aneurysms. FEVAR re-
quires scrupulous preoperative planning, advanced endo-
vascular skills, and an experienced medical team well
versed with the wide endovascular armamentarium
required to ensure success.
Table IV. Type of complications (matched cohort)
FEVAR group OSR group
1 SMA scallop malposition 1 renal artery injury
1 SMA stent migration 1 acute renal artery thrombosis
2 renal artery thrombosis 2 retroperitoneal hematoma
2 renal stent thrombosis 2 postoperative bleeding
1 renal stent disconnection 1 renal bypass thrombosis
3 iliac limb grafts thrombosis 1 early wound dehiscence
1 iliac limb disconnection
3 acute ischemia
on iliac dissection
1 acute ischemia
(femoral endarterectomy)
1 accidental internal iliac cover
FEVAR, Fenestrated endovascular aneurysm repair; OSR, open surgical
repair; SMA, superior mesenteric artery.
Table V. Multivariable models for 30-day outcomes in
matched patients
Outcome OR 95% CI P
Death
FEVAR 5.1 1.08-24 .04
Any complication
FEVAR 2.3 1.1-4.9 .03
COPD 3.3 1.7-6.7 .0008
Cardiac complication
FEVAR 0.47 0.1-2.2 .34
Pulmonary complication
FEVAR 1.19 0.41-3.5 .75
Renal complication
FEVAR 2.8 0.6-13 .2
Procedural complication
FEVAR 4.3 1.5-12 .006
MI 3.9 1.4-11 .009
COPD 4.3 1.6-11 .004
Graft complication
FEVAR 24 6.5-89 <.0001
CI, Conﬁdence interval; COPD, chronic obstructive pulmonary disease;
FEVAR, fenestrated endovascular aneurysm repair; MI, myocardial infarc-
tion; OR, odds ratio.
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excellent early and midterm outcomes, with 30-day mortal-
ity varying from 2% to 4.1%, with very encouraging tech-
nical success rates.7,16-19 Other recent series have
highlighted excellent long-term results in durability,
freedom from any reintervention, and branch stent
patency.20,21 However, most of these data represent single
high-volume center experiences or trial or registry data
with careful patient selection protocols without control
arms. Studies comparing both techniques are sparse.
In a recent retrospective cohort study, Canavati et al22
reported that FEVAR signiﬁcantly reduced mortality
compared with OSR in the treatment of juxtarenal or para-
renal aneurysms. In this small series (n ¼ 107), the re-
ported perioperative mortality of 9.5% for OSR was
signiﬁcantly higher than previously reported in a large
meta-analysis23 of pararenal aneurysms despite including20 patients (18.6%) who had undergone infrarenal clamp-
ing and should not have been included for comparison.
A larger systematic review comparing outcomes of
OSR and FEVAR repair of juxtarenal AAAs pooled results
from eight FEVAR and 12 OSR series and showed favor-
able outcomes in patients treated with FEVAR.19 These in-
vestigators, however, acknowledged signiﬁcant limitations
speciﬁcally regarding their inability to compare anatomi-
cally similar patients and selection biases inherent to the
included studies.
Our study is the ﬁrst report to comparatively evaluate
outcomes of CAAA repair in contemporary practice using
rigorous methods to compare patients both anatomically
and with similar clinical risk. Contrary to the extant litera-
ture, this study’s ﬁndings suggest that FEVAR is associated
with a higher procedural mortality, complications, and
graft-related complications compared with OSR in
propensity-matched patients.
Several of our study ﬁndings deserve further consider-
ation, the ﬁrst of which is our primary outcome measure
of procedural mortality. We found that patients undergo-
ing FEVAR had a signiﬁcantly higher operative mortality
compared with previously published single-center re-
ports20,22 and with pooled results from several systematic
reviews.16,18,19 This difference in mortality may be
explained by patient selection, speciﬁcally in regards to
aneurysm morphology. Prior FEVAR studies included a
signiﬁcant proportion of patients who did not qualify for
EVAR due to anatomic requirements, particularly shorter
necks. Early patients were therefore treated with FEVAR
to achieve adequate seal zones, primarily using fenestra-
tions and scallops to incorporate the renal arteries.16,18,19
Furthermore, each of these reports acknowledged that
more than half of the included studies did not provide
anatomic information about the proximal neck.
Our study took into account this limitation of earlier
comparative studies. Therefore, the analysis in this study
included all FEVAR patients with respect to the anticipated
clamp location for open reconstruction, thus providing
anatomic similarity. The use of such methods made it
more likely that patients in this FEVAR group would
have three visceral vessels incorporated into the proximal
seal zone, and had they required OSR, almost half would
require a supravisceral aortic cross-clamp. The use of
FEVAR for more complex aneurysm anatomy likely
contributed to the increased mortality for FEVAR we
observed.
Another major determinant for the increased FEVAR
mortality observed in this study relates to patient selection.
Earlier studies, as mentioned above, referred patients with
short necks to FEVAR; however, there was no particular
emphasis on patient ineligibility for OSR. In the present
study, patients were referred to FEVAR based on the sur-
geon’s impression that they were too high risk for OSR.
The operative volume and reported outcomes from both
centers involved in this study suggest excellent discretion,
patient selection, and operative management of patients
with CAAA; further qualifying patients as truly high clinical
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were therefore more likely to have CAD, CHF, COPD,
and chronic renal insufﬁciency compared with previous
studies. The Endovascular aneurysm repair and outcome
in patients unﬁt for open abdominal aortic aneurysm
(EVAR 2) trial4 deﬁned patients as high risk for open repair
predominantly using CAD and COPD. These investigators
reported that perioperative mortality for EVAR, a much
simpler technical procedure than FEVAR, was 9%when per-
formed in patients deemed too high risk for open infrarenal
AAA repair. This study’s results suggest that when patients
are deemed too high risk for open juxtarenal repair, they
are likely to have a high procedural mortality if referred to
FEVAR, even at a high-volume endovascular center.
Our study also helps to deﬁne patients who may be too
high risk for FEVAR. In this reported series, four FEVAR
patients died. One died of respiratory failure due to pneu-
monia after an uncomplicated procedure reﬂecting patient
factors. Three deaths, however, were related to mesenteric
infarction. None of these patients had a prior SMA or celiac
trunk stenoses. Two of them had stented SMA fenestrations,
and one had an unstented SMA scallop. No particular cathe-
terization issue or stent placement was required during the
procedure in the treatment of these patients. Immediate
postoperative imaging and CT scans performed when
patients clinically deteriorated revealedpatent SMAandceliac
vessels. Surgical exploration in these three patients revealed
patent mesenteric pulses with multiple areas of infarcted
bowel and pathology consistent with cholesterol emboli. In
the absences of cholesterol embolization, these patients
would likely have had a favorable outcome resulting in similar
operativemortality in the FEVAR andOSR cohorts. As such,
patient selection with a particular focus on anatomic consid-
erations, including navigation difﬁculties and diseased aortas
that have embolic potential, need tobe carefully considered in
the planning of potential candidates for FEVAR. These fac-
tors may play a greater role in patient outcomes than patient
comorbidities, as suggested by our experience.
With respect to procedural morbidity, this study
showed no major effect of OSR or FEVAR on organ-
speciﬁc complications. FEVAR was not protective for car-
diac or pulmonary complications, suggesting that patients
considered high risk due to these comorbidities might be
safely taken through OSR with good operative technique
and meticulous anesthesia care.
This study also indicated that FEVAR was indepen-
dently associated with increased procedural complications.
EVAR for infrarenal AAA has been associated with a higher
rate of reintervention than OSR.3 It is not surprising that,
owing to the complexity of fenestrated devices and implan-
tation procedures, reintervention rates and graft complica-
tions were also higher in the FEVAR group. Among the
42 patients in the propensity-matched endovascular cohort,
14 had graft complications #30 days; of which six were due
to visceral arteries catheterization and 5 to an iliac extension
thrombosis. Five patients had a graft malposition issue.
This study has several limitations. First, it is limited by
its retrospective nature, even if the data were collectedprospectively. Patients in this nonrandomized observa-
tional series were analyzed from two different international
centers, with different clinical practices and referral pat-
terns. Although every attempt was made to create anatom-
ically and clinically similar cohorts for analysis, comparing
patients that may differ in clinical gravity is difﬁcult. The
propensity matching was based on observed and recorded
features; yet, numerous clinical factors are taken into
consideration for surgical decision making that are not
measured and were not available for evaluation in the pro-
pensity matching. Such factors that might affect surgical
outcomes but were not included are patient functional sta-
tus, aneurysm growth rate, symptomatic status, and clinical
urgency, to name a few.
Initially, patients from the FEVAR cohort were likely
to have a higher surgical risk than patients from the OSR
group. This subset of patients likely had a higher propor-
tion of CAD, CHF, COPD, and chronic kidney disease.
They also had a higher proportion of supravisceral antici-
pated clamp position, reﬂecting the extent of the aneu-
rysmal disease. Although the two different patient
cohorts were well matched by the PS, there were likely spe-
ciﬁc anatomic and clinical characteristics that might have
been important to the FEVAR group but were not consid-
ered. It is noteworthy that there was no comparison of
target vessel anatomy or considerations related to aortic
vessel anatomy. There was no comparison of access vessel
quality, neck angulation, visceral vessel orientation, ostial
visceral occlusive disease, and aortic morphology for
comparison.
Navigation difﬁculties and graft placement in visceral
vessels are important aspects of FEVAR that might have
adversely affected only that cohort speciﬁcally in terms of
graft and procedural complications; however, this was not
corrected for. Availability of such anatomic and clinically
relevant technical differences across the procedure types
and the ability to correct for them in the propensity match-
ing would have further strengthened the analysis.
In every surgical procedure, the learning curve remains
a pivotal point that inﬂuences results and outcomes. This
series compared two different techniques in two different
centers. OSR is a well-established technique, and the large
skill set needed to procure excellent outcomes has been
well mastered. FEVAR is a more recent technique that is
in evolution and in the same treatment period had <20%
the number of cases. Furthermore, FEVAR procedures
require not only the implantation of a device as in OSR
but also a signiﬁcant amount of preoperative planning
necessitating a certain level of expertise, including
advanced skills in three-dimensional imaging, anticipation
of navigation difﬁculties, salvage maneuvers, and knowl-
edge of the graft and material limitations. All this knowl-
edge can be only be acquired over time and with a
number of failures to identify those cases that cannot be
adequately performed. The learning curve of the endovas-
cular technique was likely responsible for part of the
adverse outcomes observed in the FEVAR cohort.
Although these FEVAR and OSR procedures were
JOURNAL OF VASCULAR SURGERY
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generalizable to other centers with lower surgical volume.
CONCLUSIONS
In this propensity-matched series, FEVAR was associ-
ated with a higher mortality and an “any complication”
occurrence compared with OSR, highlighting that OSR
should be considered preferable to FEVAR for the low-
risk patient with a CAAA. Mesenteric infarction was the
principal cause of death after FEVAR. Identifying patients
with potential target vessel difﬁculties or graft complica-
tions might identify patients at risk for FEVAR. Thereby,
the extension of the infrarenal AAA treatment paradigm
shift to EVAR cannot be applied to a similar paradigm shift
of CAAA to FEVAR. Prospective studies will help to deter-
mine beneﬁts of FEVAR over OSR.
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Submitted Nov 13, 2013; accepted Apr 3, 2014.DISCUSSIONDr Gustavo Oderich (Rochester, Minn). I rise here because
your results are markedly different than what has been reported
in numerous publications, including meta-analyses, systematic re-
views, prospective studies, and national data sets. Clearly bothoperationsdopen or fenestrated repairdrequire a set of skills
and a learning curve that has to be mastered for one to achieve
outstanding results. Case selection, planning, and multidisciplinary
postoperative care can have great impact on early outcomes of
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864 Raux et al October 2014both procedures. Therefore, the obvious question is whether the
learning curve and skill set which has been achieved at the Massa-
chusetts General Hospital (MGH) with open repair of hundreds of
patients with juxtarenal, suprarenal, and thoracoabdominal aneu-
rysms over decades, has also been achieved with the ﬁrst 50 fenes-
trated cases done at your center. Clearly, at least in our experience,
I think fenestrated repair does require a learning curve, planning,
case selection, and mastering a set of skillsdeven for those that
are already skilled and experienced with other types of endovascu-
lar procedures.
The other particular question pertain the cause of death,
which in most patients was mesenteric ischemia. Do you think
this was due to embolization or ischemia from narrow or occluded
stents? We now stent all single-diameter scallops. I’ll tell you that
at least in our experience, scallops of 10-mm diameter may be asso-
ciated with mesenteric ischemia, and the safest is probably to stent
liberally.
Dr Maxime Raux. One of the major causes of death was not
mesenteric ischemia but infarction due to multiple embolisms after
catheterization, but no superior mesenteric artery was thrombosed
after the procedure. And when we made computed tomography
scans for the patients, all superior mesenteric arteries were patent,
but it is probably related to multiple emboli.
Dr John Ricotta (Washington, D.C.). That was a very nice
paper. If I interpreted correctly, what it says is if you have a patient
that is suitable for open repair, that fenestrated repair offers no
beneﬁt and may be worse. But it doesn’t address the issue of the
patient who is not suited for open repair. You had about 15 of
your patients in the fenestrated group who were not propensity
matched, so I assume that they didn’t match with anybody inthe open group. Could you tell us what happened to those pa-
tients? Could you tell us whether the mortality rate in the open
group that was not propensity matched was the same as in the pro-
pensity-matched group so that we can get some idea about that?
Dr Raux. The mortality rate in the open group was mostly the
same, but in the fenestrated endovascular repair group (FEVAR)
group, on the unmatched patient, the mortality rate was higher,
with 10.5% mortality for the unmatched patient. Maybe Professor
Becquemin would like to comment.
Dr Jean-Pierre Becquemin (Créteil, France). I have some
comments. First, I want to congratulate Maxime for this very
important work and also my colleagues from MGH for the
outstanding results. Obviously, we were disappointed by our
own results with FEVAR, which resulted in a higher than expected
mortality rate. As mentioned, this mortality rate was mostly related
to multiple atherosclerotic embolisms. It was probably a mistake to
treat some of these patients with FEVAR.
Lessons can be drawn from this study: (1) surgery can give
excellent results in expert hands, and (2) FEVAR is not an easy
procedure. It may be very tricky, even if you carefully select pa-
tients. Sometimes the target vessels, the aorta, or the access vessels
are not suitable and pushing the limits of indications may end up in
catastrophe.
Finally, I think that FEVAR has obviously a future since stent
graft technology will improve as well as the skill of surgeons per-
forming these procedures. The key selection criterion, in my
opinion, is not patients’ general status (high risk for FEVAR,
low risk for open repair), but more the anatomical suitability of
vessels. With a proper selection, results of FEVAR will probably
equal the results of open surgery in the near future.
